Some promising takeaways from our recent discussion with CZM’s IR. Despite a weaker Chinese economy, the firm is witnessing a strong rebound in refractive procedures over the past two months. Importantly, the rebound in Chinese procedure volume supports the strong sales growth outlook for the upcoming summer season. Also, CZM’s FY 23/24 P/E is close to FY 16/17 levels and, considering CZM’s enviable market position along with benefits associated with entry in the US markets, we believe the stock ....
